Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR). CREDENCE randomly assigned 4401 participants with an eGFR of 30 to <90 ml/min per 1....
Saved in:
| Published in | Journal of the American Society of Nephrology Vol. 31; no. 5; pp. 1128 - 1139 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Society of Nephrology
01.05.2020
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1046-6673 1533-3450 1533-3450 |
| DOI | 10.1681/ASN.2019111168 |
Cover
Loading…
| Abstract | Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR).
CREDENCE randomly assigned 4401 participants with an eGFR of 30 to <90 ml/min per 1.73 m
and substantial albuminuria to canagliflozin 100 mg or placebo. We used Cox proportional hazards regression to analyze effects on renal and cardiovascular efficacy and safety outcomes within screening eGFR subgroups (30 to <45, 45 to <60, and 60 to <90 ml/min per 1.73 m
) and linear mixed effects models to analyze the effects on eGFR slope.
At screening, 1313 (30%), 1279 (29%), and 1809 (41%) participants had an eGFR of 30 to <45, 45 to <60, and 60 to <90 ml/min per 1.73 m
, respectively. The relative benefits of canagliflozin for renal and cardiovascular outcomes appeared consistent among eGFR subgroups (all
interaction >0.11). Subgroups with lower eGFRs, who were at greater risk, exhibited larger absolute benefits for renal outcomes. Canagliflozin's lack of effect on serious adverse events, amputations, and fractures appeared consistent among eGFR subgroups. In all subgroups, canagliflozin use led to an acute eGFR drop followed by relative stabilization of eGFR loss. Among those with an eGFR of 30 to <45 ml/min per 1.73 m
, canagliflozin led to an initial drop of 2.03 ml/min per 1.73 m
. Thereafter, decline in eGFR was slower in the canagliflozin versus placebo group (-1.72 versus -4.33 ml/min per 1.73 m
; between-group difference 2.61 ml/min per 1.73 m
).
Canagliflozin safely reduced the risk of renal and cardiovascular events, with consistent results across eGFR subgroups, including the subgroup initiating treatment with an eGFR of 30 to <45 ml/min per 1.73 m
. Absolute benefits for renal outcomes were greatest in subgroups with lower eGFR.
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE), NCT02065791. |
|---|---|
| AbstractList | Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR).
CREDENCE randomly assigned 4401 participants with an eGFR of 30 to <90 ml/min per 1.73 m
and substantial albuminuria to canagliflozin 100 mg or placebo. We used Cox proportional hazards regression to analyze effects on renal and cardiovascular efficacy and safety outcomes within screening eGFR subgroups (30 to <45, 45 to <60, and 60 to <90 ml/min per 1.73 m
) and linear mixed effects models to analyze the effects on eGFR slope.
At screening, 1313 (30%), 1279 (29%), and 1809 (41%) participants had an eGFR of 30 to <45, 45 to <60, and 60 to <90 ml/min per 1.73 m
, respectively. The relative benefits of canagliflozin for renal and cardiovascular outcomes appeared consistent among eGFR subgroups (all
interaction >0.11). Subgroups with lower eGFRs, who were at greater risk, exhibited larger absolute benefits for renal outcomes. Canagliflozin's lack of effect on serious adverse events, amputations, and fractures appeared consistent among eGFR subgroups. In all subgroups, canagliflozin use led to an acute eGFR drop followed by relative stabilization of eGFR loss. Among those with an eGFR of 30 to <45 ml/min per 1.73 m
, canagliflozin led to an initial drop of 2.03 ml/min per 1.73 m
. Thereafter, decline in eGFR was slower in the canagliflozin versus placebo group (-1.72 versus -4.33 ml/min per 1.73 m
; between-group difference 2.61 ml/min per 1.73 m
).
Canagliflozin safely reduced the risk of renal and cardiovascular events, with consistent results across eGFR subgroups, including the subgroup initiating treatment with an eGFR of 30 to <45 ml/min per 1.73 m
. Absolute benefits for renal outcomes were greatest in subgroups with lower eGFR.
Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE), NCT02065791. The CREDENCE randomized trial demonstrated that canagliflozin reduces risk of cardiovascular and renal events in people with type 2 diabetes and substantial albuminuria. The authors analyzed CREDENCE data to assess whether canagliflozin’s benefits are safely preserved in people with reduced eGFR, finding that the relative benefits for renal and cardiovascular outcomes appeared consistent among subgroups with initial eGFR ranging from 30 to <90 ml/min per 1.73 m 2 . Absolute benefit for renal outcomes was greater in subgroups with an initial eGFR of <60 ml/min per 1.73 m 2 . Safety outcomes were generally consistent among eGFR subgroups. Canagliflozin led to an acute eGFR drop, followed by relative stabilization of eGFR loss across subgroups. Canagliflozin’s benefits and safety are apparent across the eGFR range, including among those initiating treatment with eGFR as low as 30 ml/min per 1.73 m 2 . Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR).BACKGROUNDCanagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by initial estimated glomerular filtration rate (eGFR).CREDENCE randomly assigned 4401 participants with an eGFR of 30 to <90 ml/min per 1.73 m2 and substantial albuminuria to canagliflozin 100 mg or placebo. We used Cox proportional hazards regression to analyze effects on renal and cardiovascular efficacy and safety outcomes within screening eGFR subgroups (30 to <45, 45 to <60, and 60 to <90 ml/min per 1.73 m2) and linear mixed effects models to analyze the effects on eGFR slope.METHODSCREDENCE randomly assigned 4401 participants with an eGFR of 30 to <90 ml/min per 1.73 m2 and substantial albuminuria to canagliflozin 100 mg or placebo. We used Cox proportional hazards regression to analyze effects on renal and cardiovascular efficacy and safety outcomes within screening eGFR subgroups (30 to <45, 45 to <60, and 60 to <90 ml/min per 1.73 m2) and linear mixed effects models to analyze the effects on eGFR slope.At screening, 1313 (30%), 1279 (29%), and 1809 (41%) participants had an eGFR of 30 to <45, 45 to <60, and 60 to <90 ml/min per 1.73 m2, respectively. The relative benefits of canagliflozin for renal and cardiovascular outcomes appeared consistent among eGFR subgroups (all P interaction >0.11). Subgroups with lower eGFRs, who were at greater risk, exhibited larger absolute benefits for renal outcomes. Canagliflozin's lack of effect on serious adverse events, amputations, and fractures appeared consistent among eGFR subgroups. In all subgroups, canagliflozin use led to an acute eGFR drop followed by relative stabilization of eGFR loss. Among those with an eGFR of 30 to <45 ml/min per 1.73 m2, canagliflozin led to an initial drop of 2.03 ml/min per 1.73 m2. Thereafter, decline in eGFR was slower in the canagliflozin versus placebo group (-1.72 versus -4.33 ml/min per 1.73 m2; between-group difference 2.61 ml/min per 1.73 m2).RESULTSAt screening, 1313 (30%), 1279 (29%), and 1809 (41%) participants had an eGFR of 30 to <45, 45 to <60, and 60 to <90 ml/min per 1.73 m2, respectively. The relative benefits of canagliflozin for renal and cardiovascular outcomes appeared consistent among eGFR subgroups (all P interaction >0.11). Subgroups with lower eGFRs, who were at greater risk, exhibited larger absolute benefits for renal outcomes. Canagliflozin's lack of effect on serious adverse events, amputations, and fractures appeared consistent among eGFR subgroups. In all subgroups, canagliflozin use led to an acute eGFR drop followed by relative stabilization of eGFR loss. Among those with an eGFR of 30 to <45 ml/min per 1.73 m2, canagliflozin led to an initial drop of 2.03 ml/min per 1.73 m2. Thereafter, decline in eGFR was slower in the canagliflozin versus placebo group (-1.72 versus -4.33 ml/min per 1.73 m2; between-group difference 2.61 ml/min per 1.73 m2).Canagliflozin safely reduced the risk of renal and cardiovascular events, with consistent results across eGFR subgroups, including the subgroup initiating treatment with an eGFR of 30 to <45 ml/min per 1.73 m2. Absolute benefits for renal outcomes were greatest in subgroups with lower eGFR.CONCLUSIONSCanagliflozin safely reduced the risk of renal and cardiovascular events, with consistent results across eGFR subgroups, including the subgroup initiating treatment with an eGFR of 30 to <45 ml/min per 1.73 m2. Absolute benefits for renal outcomes were greatest in subgroups with lower eGFR.Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE), NCT02065791.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBEREvaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy (CREDENCE), NCT02065791. |
| Author | Cannon, Christopher P. Charytan, David M. Bajaj, Harpreet S. Di Tanna, Gian Luca Heerspink, Hiddo J.L. Perkovic, Vlado Pollock, Carol Greene, Tom Neal, Bruce Zhang, Hong Sun, Tao Bull, Scott Bakris, George Levin, Adeera Jardine, Meg J. de Zeeuw, Dick Oshima, Megumi Agarwal, Rajiv Mahaffey, Kenneth W. Qiu, Rose Rosenthal, Norman Zhou, Zien Zinman, Bernard Wheeler, David C. |
| Author_xml | – sequence: 1 givenname: Meg J. surname: Jardine fullname: Jardine, Meg J. organization: The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia, Concord Repatriation General Hospital, Sydney, New South Wales, Australia – sequence: 2 givenname: Zien surname: Zhou fullname: Zhou, Zien organization: The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia, Department of Radiology, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China – sequence: 3 givenname: Kenneth W. surname: Mahaffey fullname: Mahaffey, Kenneth W. organization: Department of Medicine, Stanford Center for Clinical Research, Stanford University School of Medicine, Stanford, California – sequence: 4 givenname: Megumi orcidid: 0000-0002-4108-5229 surname: Oshima fullname: Oshima, Megumi organization: The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia, Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan – sequence: 5 givenname: Rajiv surname: Agarwal fullname: Agarwal, Rajiv organization: Indiana University School of Medicine and Veterans Affairs Medical Center, Indianapolis, Indiana – sequence: 6 givenname: George orcidid: 0000-0003-1183-1267 surname: Bakris fullname: Bakris, George organization: Department of Medicine, University of Chicago Medicine, Chicago, Illinois – sequence: 7 givenname: Harpreet S. orcidid: 0000-0002-1461-1465 surname: Bajaj fullname: Bajaj, Harpreet S. organization: LMC Healthcare, Leadership Sinai Centre for Diabetes, Mount Sinai Hospital, Toronto, Ontario, Canada – sequence: 8 givenname: Scott surname: Bull fullname: Bull, Scott organization: Janssen Research & Development, LLC, Raritan, New Jersey – sequence: 9 givenname: Christopher P. surname: Cannon fullname: Cannon, Christopher P. organization: Cardiovascular Division, Brigham and Women’s Hospital, Boston, Massachusetts, Baim Institute for Clinical Research, Boston, Massachusetts – sequence: 10 givenname: David M. surname: Charytan fullname: Charytan, David M. organization: Baim Institute for Clinical Research, Boston, Massachusetts, Nephrology Division, New York University Langone Medical Center, New York University School of Medicine, New York, New York – sequence: 11 givenname: Dick surname: de Zeeuw fullname: de Zeeuw, Dick organization: Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands – sequence: 12 givenname: Gian Luca orcidid: 0000-0002-5470-3567 surname: Di Tanna fullname: Di Tanna, Gian Luca organization: The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia – sequence: 13 givenname: Tom surname: Greene fullname: Greene, Tom organization: Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah – sequence: 14 givenname: Hiddo J.L. surname: Heerspink fullname: Heerspink, Hiddo J.L. organization: The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia, Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands – sequence: 15 givenname: Adeera surname: Levin fullname: Levin, Adeera organization: Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada – sequence: 16 givenname: Bruce surname: Neal fullname: Neal, Bruce organization: The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia, The Charles Perkins Centre, University of Sydney, Sydney, New South Wales, Australia, Imperial College London, London, United Kingdom – sequence: 17 givenname: Carol surname: Pollock fullname: Pollock, Carol organization: Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia, Royal North Shore Hospital, Sydney, New South Wales, Australia – sequence: 18 givenname: Rose surname: Qiu fullname: Qiu, Rose organization: Janssen Research & Development, LLC, Raritan, New Jersey – sequence: 19 givenname: Tao surname: Sun fullname: Sun, Tao organization: Janssen Research & Development, LLC, Raritan, New Jersey – sequence: 20 givenname: David C. surname: Wheeler fullname: Wheeler, David C. organization: The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia, Department of Renal Medicine, University College London Medical School, London, United Kingdom – sequence: 21 givenname: Hong surname: Zhang fullname: Zhang, Hong organization: Renal Division, Peking University First Hospital, Beijing, China – sequence: 22 givenname: Bernard surname: Zinman fullname: Zinman, Bernard organization: Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada – sequence: 23 givenname: Norman surname: Rosenthal fullname: Rosenthal, Norman organization: Janssen Research & Development, LLC, Raritan, New Jersey – sequence: 24 givenname: Vlado surname: Perkovic fullname: Perkovic, Vlado organization: The George Institute for Global Health, University of New South Wales Sydney, Sydney, New South Wales, Australia, Royal North Shore Hospital, Sydney, New South Wales, Australia |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32354987$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1Uctu1DAUjVARfcCWJfKSRTPYcWzHLJCGMC2IqpVmytq6YzutkWO3cVIp_Qi-GfdBeUjcja90z0s--8VOiMEWxWuCF4Q35N1yc7qoMJEkD2-eFXuEUVrSmuGdvOOal5wLulvsp_QdY8IqIV4Uu7SirJaN2Ct-rG0Af4haGIyLN5D05GE4RBAM2kBnxxmdTaOOvU0odhkW4MK7zsdbF9B2Rh8hWe-CRV-dCXZGR1PQo4vhPVqijdUxGBhmtMwec3L3EuOlRe169Wl12q7QOvvE3t1ag84HB_5l8bwDn-yrx_eg-Ha0Om8_lydnx1_a5Umpa8bH0kINHWCiieC8qSSRjBhmmBVs20lpCK5IU4NkElOhhWwqw6jGTSWMrg0YelB8eNC9mra9NdqGcQCvrgbX57wqglN_X4K7VBfxRomKiJrwLPD2UWCI15NNo-pd0tZ7CDZOSVVU5mgcsyZD3_zp9WTyq4QMWDwA9BBTGmz3BCFY3bWscsvqd8uZUP9D0G6Eu2_PWZ3_H-0npECrJQ |
| CitedBy_id | crossref_primary_10_1016_j_pharmthera_2022_108330 crossref_primary_10_1161_CIRCULATIONAHA_120_048740 crossref_primary_10_1038_s41598_023_42989_z crossref_primary_10_1007_s40265_021_01573_3 crossref_primary_10_1093_eurheartj_ehab497 crossref_primary_10_1111_jdi_13624 crossref_primary_10_7759_cureus_17452 crossref_primary_10_1038_s41598_024_81747_7 crossref_primary_10_3389_fendo_2022_1011669 crossref_primary_10_1002_ehf2_13483 crossref_primary_10_1097_CRD_0000000000000554 crossref_primary_10_1093_ckj_sfac044 crossref_primary_10_1097_IMNA_D_23_00029 crossref_primary_10_1016_j_ijcard_2021_12_050 crossref_primary_10_1111_joim_20050 crossref_primary_10_1016_j_biopha_2023_114252 crossref_primary_10_3389_fmed_2021_657956 crossref_primary_10_1159_000524889 crossref_primary_10_14341_DM12864 crossref_primary_10_4103_jfcm_jfcm_111_23 crossref_primary_10_1080_17512433_2022_2108402 crossref_primary_10_1177_20543581221145068 crossref_primary_10_3390_jcm11195622 crossref_primary_10_1016_j_numecd_2021_02_006 crossref_primary_10_2215_CJN_05450421 crossref_primary_10_1371_journal_pone_0295059 crossref_primary_10_1080_17446651_2022_2014322 crossref_primary_10_3390_diseases8020014 crossref_primary_10_1016_j_semerg_2023_102019 crossref_primary_10_1080_08037051_2024_2353836 crossref_primary_10_1111_dom_14539 crossref_primary_10_1016_j_jacc_2022_08_772 crossref_primary_10_1097_MNH_0000000000000861 crossref_primary_10_1186_s40001_024_02214_7 crossref_primary_10_1111_eci_14335 crossref_primary_10_1161_HYPERTENSIONAHA_121_17005 crossref_primary_10_1111_nep_13917 crossref_primary_10_1111_nep_14207 crossref_primary_10_4070_kcj_2023_0241 crossref_primary_10_1016_j_xkme_2021_04_009 crossref_primary_10_1152_ajpcell_00147_2023 crossref_primary_10_1186_s12933_023_01879_4 crossref_primary_10_1177_03000605241227659 crossref_primary_10_5937_hpimj2403483D crossref_primary_10_1016_j_diabres_2023_110576 crossref_primary_10_3390_ijms232213749 crossref_primary_10_1016_S2213_8587_24_00102_5 crossref_primary_10_1080_00325481_2024_2426442 crossref_primary_10_2337_cd21_0090 crossref_primary_10_2337_dc22_0942 crossref_primary_10_7759_cureus_17668 crossref_primary_10_2215_CJN_10140620 crossref_primary_10_3390_ijms25136926 crossref_primary_10_3390_biom15010039 crossref_primary_10_1002_jcp_30621 crossref_primary_10_3390_ijms23073915 crossref_primary_10_1097_FJC_0000000000001329 crossref_primary_10_2174_0929867330666221227091943 crossref_primary_10_3390_jpm11121249 crossref_primary_10_1007_s13300_021_01198_5 crossref_primary_10_1007_s40264_020_01010_6 crossref_primary_10_3390_ijms23052812 crossref_primary_10_1038_s41581_022_00535_6 crossref_primary_10_3724_abbs_2022140 crossref_primary_10_2217_fca_2020_0192 crossref_primary_10_1007_s13300_023_01391_8 crossref_primary_10_2174_0125899775332399240806101923 crossref_primary_10_1016_j_kint_2020_11_021 crossref_primary_10_1007_s12325_021_02006_z crossref_primary_10_1161_STROKEAHA_120_031623 crossref_primary_10_1093_eurheartj_ehab561 crossref_primary_10_1016_S2213_8587_23_00321_2 crossref_primary_10_1002_14651858_CD015588_pub2 crossref_primary_10_1093_ehjcvp_pvae003 crossref_primary_10_3390_ijms241713074 crossref_primary_10_1177_20420188211044945 crossref_primary_10_1186_s12882_021_02369_z crossref_primary_10_3389_fendo_2024_1429261 crossref_primary_10_1681_ASN_2022020135 crossref_primary_10_1093_ndt_gfad026 crossref_primary_10_1016_j_diabres_2024_111933 crossref_primary_10_2215_CJN_08980621 crossref_primary_10_1002_14651858_CD013650_pub2 crossref_primary_10_1016_j_jvscit_2021_10_006 crossref_primary_10_1186_s13098_022_00929_3 crossref_primary_10_1007_s11357_023_00803_8 crossref_primary_10_3390_jcm9072243 crossref_primary_10_1038_s41581_021_00462_y crossref_primary_10_1007_s13300_020_00826_w crossref_primary_10_3389_fendo_2022_1063341 crossref_primary_10_1186_s12933_022_01676_5 crossref_primary_10_1093_ejendo_lvad078 crossref_primary_10_1038_s41581_024_00836_y crossref_primary_10_1053_j_ackd_2021_06_002 crossref_primary_10_1186_s12933_020_01163_9 crossref_primary_10_1093_ckj_sfab096 crossref_primary_10_2215_CJN_0000000000000568 crossref_primary_10_1016_j_kint_2020_10_042 crossref_primary_10_1007_s10157_023_02419_w crossref_primary_10_1016_S2213_8587_20_30185_6 crossref_primary_10_2215_CJN_15260920 crossref_primary_10_3748_wjg_v28_i39_5691 crossref_primary_10_1016_j_ekir_2022_09_018 crossref_primary_10_1038_s41467_024_52447_7 crossref_primary_10_1111_dom_14986 crossref_primary_10_2337_dc21_2034 crossref_primary_10_1111_dom_14741 crossref_primary_10_1111_jdi_13795 crossref_primary_10_1186_s12933_022_01476_x crossref_primary_10_3389_fmed_2021_777861 crossref_primary_10_1007_s10157_023_02380_8 |
| Cites_doi | 10.1007/s11906-019-0920-4 10.1056/NEJMoa1504720 10.1056/NEJMoa1811744 10.1152/physrev.1990.70.3.665 10.1172/JCI113120 10.1161/CIRCULATIONAHA.116.021887 10.1681/ASN.2016030278 10.1530/EJE-17-0832 10.1056/NEJMoa1611925 10.1159/000484633 10.1159/000364909 10.1038/ki.2011.79 10.1016/j.celrep.2018.09.058 10.1056/NEJMoa1812389 10.1007/s00125-018-4656-5 10.1161/CIRCULATIONAHA.113.005081 |
| ContentType | Journal Article |
| Contributor | Heerspink, Hiddo J L Luca di Tanna, Gian Perkovic, Vlado Jardine, Meg J Bajaj, Harpreet S Cannon, Christopher P Pollock, Carol Charytan, David M Greene, Tom Neal, Bruce Zhang, Hong Mahaffey, Kenneth W Sun, Tao Bull, Scott Bakris, George Levin, Adeera de Zeeuw, Dick Wheeler, David C Oshima, Megumi Agarwal, Rajiv Qiu, Rose Rosenthal, Norman Zhou, Zien Zinman, Bernard |
| Contributor_xml | – sequence: 1 givenname: Meg J surname: Jardine fullname: Jardine, Meg J – sequence: 2 givenname: Zien surname: Zhou fullname: Zhou, Zien – sequence: 3 givenname: Kenneth W surname: Mahaffey fullname: Mahaffey, Kenneth W – sequence: 4 givenname: Megumi surname: Oshima fullname: Oshima, Megumi – sequence: 5 givenname: Rajiv surname: Agarwal fullname: Agarwal, Rajiv – sequence: 6 givenname: George surname: Bakris fullname: Bakris, George – sequence: 7 givenname: Harpreet S surname: Bajaj fullname: Bajaj, Harpreet S – sequence: 8 givenname: Scott surname: Bull fullname: Bull, Scott – sequence: 9 givenname: Christopher P surname: Cannon fullname: Cannon, Christopher P – sequence: 10 givenname: David M surname: Charytan fullname: Charytan, David M – sequence: 11 givenname: Dick surname: de Zeeuw fullname: de Zeeuw, Dick – sequence: 12 givenname: Gian surname: Luca di Tanna fullname: Luca di Tanna, Gian – sequence: 13 givenname: Tom surname: Greene fullname: Greene, Tom – sequence: 14 givenname: Hiddo J L surname: Heerspink fullname: Heerspink, Hiddo J L – sequence: 15 givenname: Adeera surname: Levin fullname: Levin, Adeera – sequence: 16 givenname: Bruce surname: Neal fullname: Neal, Bruce – sequence: 17 givenname: Carol surname: Pollock fullname: Pollock, Carol – sequence: 18 givenname: Rose surname: Qiu fullname: Qiu, Rose – sequence: 19 givenname: Tao surname: Sun fullname: Sun, Tao – sequence: 20 givenname: David C surname: Wheeler fullname: Wheeler, David C – sequence: 21 givenname: Hong surname: Zhang fullname: Zhang, Hong – sequence: 22 givenname: Bernard surname: Zinman fullname: Zinman, Bernard – sequence: 23 givenname: Norman surname: Rosenthal fullname: Rosenthal, Norman – sequence: 24 givenname: Vlado surname: Perkovic fullname: Perkovic, Vlado |
| Copyright | Copyright © 2020 by the American Society of Nephrology. Copyright © 2020 by the American Society of Nephrology 2020 |
| Copyright_xml | – notice: Copyright © 2020 by the American Society of Nephrology. – notice: Copyright © 2020 by the American Society of Nephrology 2020 |
| CorporateAuthor | on behalf of the CREDENCE Study Investigators CREDENCE Study Investigators |
| CorporateAuthor_xml | – name: on behalf of the CREDENCE Study Investigators – name: CREDENCE Study Investigators |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1681/ASN.2019111168 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1533-3450 |
| EndPage | 1139 |
| ExternalDocumentID | PMC7217416 32354987 10_1681_ASN_2019111168 |
| Genre | Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Janssen Research and Development |
| GroupedDBID | --- .55 .GJ 0R~ 18M 29L 2WC 34G 39C 53G 5GY 5RE 5VS 6PF AAQQT AAUIN AAWTL AAYXX ABBLC ABJNI ABOCM ABXYN ACGFO ACLDA ACZKN ADBBV AENEX AFEXH AFFNX AFNMH AHOMT AHQVU ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW BYPQX CITATION CS3 DIK DU5 E3Z EBS EJD ERAAH F5P GX1 H13 HYE HZ~ K-O KQ8 O9- OK1 OVD P0W P2P RHI RPM TEORI TNP TR2 W8F X7M XVB YFH ZGI CGR CUY CVF ECM EIF NPM 7X8 5PM ADSXY |
| ID | FETCH-LOGICAL-c456t-ea4afa01c17668291951d5d5e75bf99d102184a959037c7982d53c0827dc4dad3 |
| ISSN | 1046-6673 1533-3450 |
| IngestDate | Thu Aug 21 18:34:05 EDT 2025 Fri Jul 11 12:27:57 EDT 2025 Mon Jul 21 05:48:28 EDT 2025 Tue Jul 01 04:34:57 EDT 2025 Thu Apr 24 22:52:33 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 5 |
| Keywords | chronic kidney disease end-stage kidney disease SGLT2 inhibitor diabetes canagliflozin |
| Language | English |
| License | Copyright © 2020 by the American Society of Nephrology. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c456t-ea4afa01c17668291951d5d5e75bf99d102184a959037c7982d53c0827dc4dad3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3 See Supplemental Material for a full list of CREDENCE Study Investigators. |
| ORCID | 0000-0003-1183-1267 0000-0002-4108-5229 0000-0002-1461-1465 0000-0002-5470-3567 |
| OpenAccessLink | https://jasn.asnjournals.org/content/jnephrol/31/5/1128.full.pdf |
| PMID | 32354987 |
| PQID | 2397666058 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7217416 proquest_miscellaneous_2397666058 pubmed_primary_32354987 crossref_primary_10_1681_ASN_2019111168 crossref_citationtrail_10_1681_ASN_2019111168 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-05-01 |
| PublicationDateYYYYMMDD | 2020-05-01 |
| PublicationDate_xml | – month: 05 year: 2020 text: 2020-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of the American Society of Nephrology |
| PublicationTitleAlternate | J Am Soc Nephrol |
| PublicationYear | 2020 |
| Publisher | American Society of Nephrology |
| Publisher_xml | – name: American Society of Nephrology |
| References | Heerspink (B8-20230829) 2017; 28 Brenner (B13-20230829) 1990; 70 Neal (B18-20230829) 2017; 377 Wiviott (B20-20230829) 2019; 380 Perkovic (B10-20230829) 2019; 380 Ortola (B14-20230829) 1987; 80 Holtkamp (B9-20230829) 2011; 80 Ghezzi (B1-20230829) 2018; 61 Chakraborty (B17-20230829) 2018; 25 Cherney (B12-20230829) 2014; 129 Jardine (B11-20230829) 2017; 46 Sternlicht (B15-20230829) 2019; 21 Esterline (B16-20230829) 2018; 178 Yamout (B2-20230829) 2014; 40 Heerspink (B7-20230829) 2016; 134 Zinman (B19-20230829) 2015; 373 |
| References_xml | – volume: 21 start-page: 12 year: 2019 ident: B15-20230829 article-title: Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): More than osmotic diuresis publication-title: Curr Hypertens Rep doi: 10.1007/s11906-019-0920-4 – volume: 373 start-page: 2117 year: 2015 ident: B19-20230829 article-title: Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa1504720 – volume: 380 start-page: 2295 year: 2019 ident: B10-20230829 article-title: Canagliflozin and renal outcomes in type 2 diabetes and nephropathy publication-title: N Engl J Med doi: 10.1056/NEJMoa1811744 – volume: 70 start-page: 665 year: 1990 ident: B13-20230829 article-title: Diverse biological actions of atrial natriuretic peptide publication-title: Physiol Rev doi: 10.1152/physrev.1990.70.3.665 – volume: 80 start-page: 670 year: 1987 ident: B14-20230829 article-title: Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration publication-title: J Clin Invest doi: 10.1172/JCI113120 – volume: 134 start-page: 752 year: 2016 ident: B7-20230829 article-title: Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: Cardiovascular and kidney effects, potential mechanisms, and clinical applications publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.116.021887 – volume: 28 start-page: 368 year: 2017 ident: B8-20230829 article-title: Canagliflozin slows progression of renal function decline independently of glycemic effects publication-title: J Am Soc Nephrol doi: 10.1681/ASN.2016030278 – volume: 178 start-page: R113 year: 2018 ident: B16-20230829 article-title: Mechanisms in endocrinology: SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism? publication-title: Eur J Endocrinol doi: 10.1530/EJE-17-0832 – volume: 377 start-page: 644 year: 2017 ident: B18-20230829 article-title: Canagliflozin and cardiovascular and renal events in type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa1611925 – volume: 46 start-page: 462 year: 2017 ident: B11-20230829 article-title: The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics publication-title: Am J Nephrol doi: 10.1159/000484633 – volume: 40 start-page: 64 year: 2014 ident: B2-20230829 article-title: Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy publication-title: Am J Nephrol doi: 10.1159/000364909 – volume: 80 start-page: 282 year: 2011 ident: B9-20230829 article-title: An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function publication-title: Kidney Int doi: 10.1038/ki.2011.79 – volume: 25 start-page: 677 year: 2018 ident: B17-20230829 article-title: Salt-responsive metabolite, β-hydroxybutyrate, attenuates hypertension publication-title: Cell Rep doi: 10.1016/j.celrep.2018.09.058 – volume: 380 start-page: 347 year: 2019 ident: B20-20230829 article-title: Dapagliflozin and cardiovascular outcomes in type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMoa1812389 – volume: 61 start-page: 2087 year: 2018 ident: B1-20230829 article-title: Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2 publication-title: Diabetologia doi: 10.1007/s00125-018-4656-5 – volume: 129 start-page: 587 year: 2014 ident: B12-20230829 article-title: Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus publication-title: Circulation doi: 10.1161/CIRCULATIONAHA.113.005081 |
| SSID | ssj0015277 |
| Score | 2.6187062 |
| Snippet | Canagliflozin reduced renal and cardiovascular events in people with type 2 diabetes in the CREDENCE trial. We assessed efficacy and safety of canagliflozin by... The CREDENCE randomized trial demonstrated that canagliflozin reduces risk of cardiovascular and renal events in people with type 2 diabetes and substantial... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1128 |
| SubjectTerms | Adult Aged Albuminuria - drug therapy Albuminuria - physiopathology Canagliflozin - adverse effects Canagliflozin - therapeutic use Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Clinical Research Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetic Nephropathies - drug therapy Diabetic Nephropathies - physiopathology Diabetic Nephropathies - prevention & control Double-Blind Method Female Humans Kidney - physiopathology Kidney Tubules, Proximal - drug effects Kidney Tubules, Proximal - metabolism Male Middle Aged Risk Sodium-Glucose Transporter 2 Inhibitors - adverse effects Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Treatment Outcome |
| Title | Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32354987 https://www.proquest.com/docview/2397666058 https://pubmed.ncbi.nlm.nih.gov/PMC7217416 |
| Volume | 31 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZB6UvY_dlNzQY7CF15_tlb1nXUjrSQpZC34wsS40hsctqPzQ_Yr9lP3HnyJYvWwPbXkxiKxL2-SKd8-k7x4S8twLJeJBKA6Ll0HATmxkRfsWkRVcyCSE05g7PzvyTC_f00rscjX72VEtVmRzwzZ15Jf9jVTgHdsUs2X-wbNspnIDPYF84goXh-Fc2notc1etH2UZPVdoqMplEQeZ5VcLgdXFZLEZwtcrkqthkObqen5nKSBeTr1maw_xwDOuc1ntMkY0vkGm4HRQvQV_1cH70RbFTcxipWGcbcFwXeMtbvN1eBkveSkWRrRCApgG1f4r3UvOsM3E16VHbRaW2UrIue23GlkzKmnVvMowmLWl0frPM1qzpp1pnfYLDNjs54YHQk7ID4KkL1OpZu1k7sv6-uJqCwYEM71wb_BDXhum3MxT04Rxv-YOG8GCv1wopju1A2Nw4AsNq3PrSPXLfhsDE0vxQs2_lwcmmNCgM93E42B7Z1T8fekF_hDa_K3R7Ls_iIXnQWI9Oa-A9IiORPya7s0aN8YT8UPjbp0P07VNABK2xRzX2aCHpAHs0uaUae7TGHtXY-0SntEUe1cjDLgBFVCOPdsijCnlPycXx0eLwxGje72FwcNtLQzCXSWZaHIuUhnZkgbefeqknAi-RUZRain9gkReZTsCDKLRTz-HgswYpd1OWOs_ITl7k4gUK9FwzZBzpg8R1TZ4ohQGsVh5HD5qNiaGfd8yb4vf4DpZVjEEwmCoGU8WdqcbkQ9v-ui77srXlO22-GGZm3G5juSiqm9hGV99H2cGYPK_N2falcTAmwcDQbQOs-j68kmdLVf09QBLB8l9u7fMV2ev-Rq_JTvm9Em_Acy6TtwqsvwAvG8Ne |
| linkProvider | National Library of Medicine |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Renal%2C+Cardiovascular%2C+and+Safety+Outcomes+of+Canagliflozin+by+Baseline+Kidney+Function%3A+A+Secondary+Analysis+of+the+CREDENCE+Randomized+Trial&rft.jtitle=Journal+of+the+American+Society+of+Nephrology&rft.au=Jardine%2C+Meg+J&rft.au=Zhou%2C+Zien&rft.au=Mahaffey%2C+Kenneth+W&rft.au=Oshima%2C+Megumi&rft.date=2020-05-01&rft.eissn=1533-3450&rft.volume=31&rft.issue=5&rft.spage=1128&rft_id=info:doi/10.1681%2FASN.2019111168&rft_id=info%3Apmid%2F32354987&rft.externalDocID=32354987 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1046-6673&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1046-6673&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1046-6673&client=summon |